Development of Multi-epitope Subunit Vaccine Against *Pseudomonas aeruginosa* Using OprF/OprI and PopB Proteins

Fattaneh Sabzehali^{1,2}, Hossein Goudarzi^{1,2}, Alireza Salimi Chirani^{1,2}, Mohammad Hossein Yoosefi Izad^{1,2} and Mehdi Goudarzi^{1,2,*}

¹Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: gudarzim@yahoo.com

Received 2021 August 10; Revised 2021 August 26; Accepted 2021 August 29.

Abstract

Background: The emerging problem of antibiotic resistance in *Pseudomonas aeruginosa* is a global health concern; hence, revealing innovative therapeutic approaches (such as designing an immunogenic vaccine candidate) is needed. There is no evidence of the availability of an effective vaccine that can combat the infection caused by this microorganism.

Objectives: This research was conducted to develop a potential chimeric vaccine against *P. aeruginosa* using reverse vaccinology approaches.

Methods: The present vaccine candidate comprised outer membrane protein F and I (OprF/OprI) and PopB with appropriate linkers. After applying meticulous immune-informatics investigation, the multi-epitope vaccine was created, including helper T lymphocyte (HTL), cytotoxic T lymphocyte (CTL), interferon gamma (IFN- γ), and interleukin 4 (IL-4) epitopes. Then, the physicochemical characteristics, allergenicity, toxicity, and antigenicity were analyzed. After investigating the secondary structure, the tertiary structure (3D) model was generated, refined, and validated via computational methods. Besides, the strong protein-ligand interaction and stability between the vaccine candidate and toll-like receptor 4 (TLR4) were determined via molecular docking and dynamics analyses. Moreover, in silico cloning accompanied by pET-22b(+) was used to achieve high translation efficiency.

Results: Our results presumed that the chimeric-designed vaccine was thermostable and contained optimal physicochemical properties. This vaccine candidate was nontoxic and highly soluble and had stable protein and TLR4 interaction, adequately overexpressed in *Escherichia coli*. Overall, it could induce immune responses and repress this microorganism.

Conclusions: Therefore, to inhibit *Pseudomonas* infections experimentally, the efficacy and safety of the vaccine design need to be validated.

Keywords: *Pseudomonas aeruginosa*, Recombinant Vaccine, Epitopes, GM-CSF, Vaccine

1. Background

Respiratory and burn infections caused by *Pseudomonas aeruginosa* are a major source of concern globally (1, 2). According to numerous studies, the mortality rate of ventilator-associated pneumonia (VAP) with *P. aeruginosa* is higher than 13.5% (3). Moreover, burn victims can immediately become infected with a systemic infection with a 38 to 70% mortality rate (4). It is noted that the treatment of *P. aeruginosa* infections with the conventional use of antibiotics has become a significant challenge due to the ability of this bacterium to resist (5-7). The intrinsic and acquired resistance in this bacterium consists of producing antibiotic-inactivating enzymes, expression of efflux pumps, low permeability in the outer membrane, and mutations and horizontal transfers of resistance genes.

The formation of biofilm causes a diffusion barrier to restrict antibiotic entrance to bacterial cells. Furthermore, multidrug-tolerant persister cells are subject to prolonged and recurrent infections in cystic fibrosis patients (8). Therefore, producing an efficacious vaccine or another alternative immunotherapy to combat the spread of *P. aeruginosa* infection is necessarily required.

So far, numerous vaccine candidates, including pili, flagella, alginate, outer membrane proteins (OMPs), etc., have been examined for *P. aeruginosa*. Since *P. aeruginosa* uses various pathways to produce infection and escape from immune system particles, no report authorizes a vaccine (9). OprF can bind peptidoglycan to the outer membrane, and OprI can play an essential role in susceptibility to antimicrobial peptides (10). These fragments have been

selected to induce various immune effectors, including opsonophagocytic killing antibodies. Moreover, the PopB of the type III secretion system has been chosen to incite high interleukin 17 (IL-17) production, increasing the recruitment of neutrophils to the site of inflammation and protecting the animal model from lethal *P. aeruginosa*. Since the interaction between secretory proteins or exposed surfaces with host cells is critical in pathogenicity, bioinformatics approaches and tools can apply to obtain new insights into these interactions and their performances in vaccine design investigations.

Due to immune modulation effects, recruitment of dendritic cells (DCs), migration to lymph node regions, and low toxicity profiles, the granulocyte-macrophage colony-stimulating factor (GM-CSF) displays an attractive vaccine adjuvant (11).

2. Objectives

Algorithm development to create new vaccines is one of the principal bioinformatics objectives. Recognizing reliable epitopes through bioinformatics analysis decreases the costs of laboratory testing. In the present study, bioinformatics tools were implemented to construct a proper vaccine using OprF, OprI, and PopB proteins of *P. aeruginosa*, accompanied by GM-CSF as an adjuvant. In this regard, according to these protein structures, the main physicochemical and immunological epitopes were predicted and evaluated, resulting in a new structure as a vaccine candidate against *P. aeruginosa*.

3. Methods

3.1. Protein Sequence Retrieval

Antigens acquired for this study are as follows: OprF (accession number: P13794), OprI (accession number: P11221), and PopB (accession number: Q9I324) as primary sequences and GM-CSF (accession number: A0A0B4U6M2) as an adjuvant. The protein sequences were obtained from UniProtKB (<https://www.uniprot.org>) and then stored as a FASTA format for additional analysis.

3.2. B-Cell (Linear) Epitope Prediction

B-lymphocytes play a crucial role in recognizing soluble antigens by producing antibodies. Neutralization and phagocytosis with or without complement can occur by these components. Two forms of B-cell epitopes were identified, consisting of linear B-cell epitopes (containing sequential residues) and conformational (discontinuous) B-cell epitopes (including patches of

solvent-accessible atoms). The accurate identification of linear B-cell epitopes was achieved by utilizing physicochemical properties of amino acids via BcePred software (<http://ailab.ist.psu.edu/bcpred/predict.html>) (12) and ABCpred server (<http://crdd.osdd.net/raghava/abcpred/>) with an artificial neural network (cutoff score > 0.7) (13).

3.3. Assessment of Antigenicity and Allergenicity

Since antigenicity evaluation is the main stage of vaccine design, VaxiJen version 2.0, AllerTOP version 2, and AllgPred online server prediction were used to ensure that the vaccine did not evoke any allergic response (14-16).

3.4. Solubility and Physicochemical Parameters Prediction

To evaluate various physicochemical characteristics of the vaccine sequence, Protein-Sol (<http://protein-sol.manchester.ac.uk>) (17) and ProtParam (<http://web.expasy.org/protparam/>) (18) were used. The population average for Protein-Sol was 0.45 (as a default), and Protein-Sol computed various chemical and physical parameters, including the molecular weight, grand average of hydropathicity (GRAVY), and so on.

3.5. Protein Secondary Structure Prediction

To estimate the secondary structural contents, the GOR V server (<http://cib.cf.ocha.ac.jp/bitool/GOR/>) based on the Garnier, Osguthorpe, and Robson method was used (19).

3.6. Vaccine 3D Structure Prediction

Predicting the 3D structure of the protein was developed using the Iterative Threading ASSEmbly Refinement (I-TASSER) server, which experimentally identifies the query protein from the template structure of the Protein Data Bank (PDB) via incorporating the Local MEta-Threading Server (LOMETS) (20). To visualize the 3D structure, we applied the PyMol software package (21).

3.7. Protein Structure Quality and Validation

The refinement process for the selected protein model was examined in the GalaxyRefine web server (<http://galaxy.seoklab.org/>). The primary proteins rebuilt side chains via locating the highest-probability rotamers, produced side-chain repacking, and relaxed the refinement construct via 2 methods: moderate relaxation or an aggressive one (22). The ultimate model was validated by the following computational tools. The ProSA-web server (<https://prosa.services.came.sbg.ac.at/prosa.php>) was used to recognize errors in the 3D models. Overall model quality, outside a range, is essential for primary proteins presenting inaccurate structures (23). The identification

of disfavored protein side-chain rotamers, all-atom contact assessment with specific hydrogens (consisting clash score), Ramachandran plot, and MolProbity score were calculated via the MolProbity structure-validation web service.

3.8. B-Cell (Discontinuous or Conformational) Epitope Prediction

The ElliPro web-accessible server (<http://tools.iedb.org/ellipro/>) was implemented as a web-accessible application to predict 3D structures via the determination of the protrusion index (PI; residues with highest scores chosen) and clustered based on their PI values and the distance R of each (24).

3.9. Major Histocompatibility Complex Class I Binding (Cytotoxic T Lymphocyte) Epitopes Prediction

The prediction of cytotoxic T lymphocyte (CTL) epitopes in OprF, OprI, and PopB proteins of *P. aeruginosa* was performed using the NetCTL 1.2 server (<http://www.cbs.dtu.dk/services/NetCTL/>), which has a crucial role in bacterial clearance in cystic fibrosis. This server is connected with antigen processing [transporter associated with antigen processing (TAP)] transport or proteasomal cleavage mechanisms to evaluate the prediction of antigen processing and presentation via the major histocompatibility complex (MHC) class I pathway. Weight on cleavage in this method was estimated at 0.15, epitope identification value at 0.72, and TAP transport at 0.05 (25).

3.10. MHC Class II Binding (Helper T Lymphocyte) Epitopes Prediction

The 15-mer helper T lymphocyte (HTL) of structural OMPs and PopB was recognized by applying the IEDB web server (<http://tools.iedb.org/mhcii/>), a popular MHC class II binding prediction tool. The sum of 7 reference sets of human leukocyte antigen (HLA) alleles of the related server, including HLA-DRB1 (*03: 01, *07: 01, and *15: 01), HLA-DRB3 (*01: 01 and *02: 02), HLA-DRB4*01: 01, and HLA-DRB5*01: 01, was preferred for MHC II binding epitope prediction. The stabilized matrix method (SMM) was used to evaluate the half-maximal inhibitory concentration (IC₅₀) value of the selected peptide connecting to MHC-II alleles, and the IC₅₀ value less than 500 nM was considered a good affinity (26).

3.11. Interferon Gamma Prediction

The interferon-gamma (IFN- γ) cytokine plays a significant role in combating chronic *P. aeruginosa* infection by adjusting immune response approaching an overall T helper (Th) 1 pattern. The production

of IFN- γ induced activation of macrophages, DCs, and natural killer (NK) cells. The IFN- γ epitope server (<https://webs.iitd.edu.in/raghava/ifnepitope/application.php>) was applied to distinguish the low scores of HTL epitopes. Positive results were predicted based on the hybrid strength of support vector machine (SVM) and motif-based techniques. Therefore, the ultimate HTL epitopes were chosen based on MHC class II binding and IFN- γ induction, both of which promote the stimulation of Th cells (27).

3.12. Immune Simulation

To predict the final vaccine-elicited immune responses in natural conditions, computational modeling on the human immune system was accomplished via the C-ImmSim online server (<https://kraken.iac.rm.cnr.it/C-IMMSIM/>). Due to the Celada-Seiden model available in this server, humoral and cellular immunity of mammalian host defense can be represented upon a vaccine design. Three injections during 2-week intervals, including 1000 vaccine proteins, were administered through the simulation default parameters (with time step set at 1, 84, and 170 with a sum of 1050 simulation steps). Furthermore, the production of antibodies and cytokines was determined upon the injection of the chimeric vaccine (28).

3.13. Interaction Analysis of Chimeric Vaccine with TLR4

A molecular docking study was implemented using the ClusPro server (<https://cluspro.bu.edu/login.php?redir/queue.%20php>). Docking was performed with TLR4 (PDB ID code: 4G8A), which acts as a receptor to recognize antigenic molecules. This server is a useful computational tool that investigated the models based on desolvation energy and electrostatic interactions. The refined complexes were presented by ClusPro based on numerous agents, including atomic contact energy, hydrophobic-favored, electrostatic-favored, and VDW plus ELEC (29).

3.14. Molecular Dynamics of Receptor-Vaccine Complex Simulation

The molecular dynamics (MD) simulation study was administered for the subunit vaccine structure manifested the best molecular docking investigation outcomes. The iMODS web server (<http://imods.chaconlab.org/>) was used to determine and assess protein flexibility (30).

3.15. Codon Optimization and In Silico Vaccine Expression

The optimization of the codon procedure was applied to express the recombinant protein using the Codon Adaptation Tool (JCat) server (<http://www.jcat.de/>). The codon adaptation index (CAI) values with the best value of 1.0 and guanine-cytosine (GC) contents ranging from 30 - 70% were used to manage protein expression levels (31). It is noted that the result beyond this scope does not have good efficiencies on translation and transcription steps. The chimeric vaccine construct was optimized based on the bacterial expression host and *Escherichia coli* codon usage by Gene Designer-v1 software. After codon optimization, HindIII and KsaI restriction sites were added in the 5' and 3' end of the chimeric gene to the N- and C-terminal sequence, according to the Webcutter2 server. Furthermore, 6 poly-histidine (His) residues were appended to the C-terminal region at the ends of the sequence for more valid affinity purification. At last, the ultimate vaccine was cloned into the pET-22b (+) plasmid using SnapGene software (<https://www.snapgene.com/try-snapgene/>) to prove the expression procedure (32).

4. Results

4. Vaccine Design

This study is an experimental study. Figure 1 illustrates the procedure of vaccine design.

4.1. Multi-epitope Vaccine Conception

The best 33 epitopes revealed a score below 0.4 (Appendices 1 and 2) that produced Vaxijen antigenicity analysis. The HTL epitopes were evaluated for HLA-DRB1 (*03: 01, *07: 01, and *15: 01), HLA-DRB3 (*01: 01 and *02: 02), HLA-DRB4*01: 01, and HLA-DRB5*01: 01 subtypes. The highest binding capability was the main point to classify the lowest scores of the best epitopes. Due to positive IFN- γ and IL-4 inductions, the best candidate was selected (Appendix 1). The CTL epitope (9-mer) prediction was performed via the NetCTL-1.2 server and IEDB (Appendix 2). We utilized both BepiPred and ABCpred servers to recognize linear B-cell epitopes. All predictions of these servers were analyzed, and merely the overlapping epitopes were chosen to develop the vaccine. The 4 common epitopes in BepiPred and ABCpred contained prediction scores with a range of 0.5 to 1 and 0.52 to 0.93 were selected. Out of the whole, 18 epitopes were chosen as final components (Table 1). To create the subunit vaccine, we applied a suitable adjuvant and linkers (Figure 2). The N-terminal region begins with methionine (Met) attached to GM-CSF as an adjuvant by

the EAAAK linker. Next, between the adjuvant and the primary CTL epitope, the GGGS linker was inserted. Three CTL epitopes attached using AAY linkers were joined to the primary HTL epitope by the HEYGAEALERAG linker. The GPGPG linker assisted the connection of all 11 HTL epitopes. Moreover, 4 ABCpred and BcePred epitopes were linked via the KK linker. Ultimately, the C-terminal region included a poly-His tail connected via the HEYGAEALERAG linker. The length of the ultimate vaccine structure was 481 amino acids.

4.2. Assessment of Allergenicity, Antigenicity, and Physicochemical Characteristics of the Vaccine

The AlgPred and AllerTOP servers found out the allergenic constitution of the vaccine. The vaccine at a threshold value of 0.4 was nonallergic with 94.18% accuracy. Furthermore, the antigenic feature of the designed vaccine structure at the default threshold value of 0.4 was 0.8421 (probable antigen), which indicated that the protein was a favorable antigen.

Besides, the designed vaccine construct included 481 amino acids. The theoretical isoelectric point and molecular weights were 6.24 and 50.83 kDa. The vaccine included 52 positively and 59 negatively charged residues. In addition, the vaccine-designed construct was formed of 7049 atoms with the chemical formula C2212H3473N649O700S15. The measured instability index was 31.92, which proved that it was stable. Moreover, the evaluated half-life was 30 hours in vitro, greater than > 20 hours in yeast and > 10 hours in *E. coli*. It was noted that the high thermostability was approved via the aliphatic index (69.79). According to the GRAVY value, which was shown to be -0.414 in this study, it revealed the hydrophobicity of the protein.

4.3. Analyses of Immune Response

It was determined that the results of the C-ImmSim server were consistent with previous laboratory studies that announced the immune responses in *P. aeruginosa* infections. High titers of immunoglobulin (G, M, G1, and G1+G2) antibodies were recognized, resulting in a decrease in antigen concentration (Figure 3A). Therefore, an extension in the population of active B cells was identified, and memory B cell was specially raised (Figures 3B and C). A related behavior was recognized for HTL and CTL (Figures 3D and E), which indicated that the population of T cells was extremely responsive since the memory was produced. Through multiple exposures, IL-12, the concentration of IFN- γ , and the population of Th1 were sustained

Figure 1. The strategy of vaccine construction.

Table 1. Final Selected Cytotoxic T Lymphocyte, Helper T Lymphocyte, ABCpred, and BcePred Epitopes Overlapping with Each Other and with B-Cell Epitopes

CTL Epitope	Vaxijen	HTL Epitopes	Vaxijen	ABCpred/BcePred	Vaxijen
LTDDVELAL	0.4731	GGRVNAVGYGESRPV	1.1297	VELALSYGEYHDVRGT	1.0432
VRDVLVNEY	0.5999	VEGGRVNAVGYGESR	1.2633	VGYGESRPVADNATAE	0.7755
AQARADEAY	0.8764	EGGRVNAVGYGESRP	1.1695	LDAIYHFGTPGVGLRP	0.5930
		TPGVGLRPVVSAGLA	1.2267	TGCSSHSKETEARLTA	1.8168
		GCSSHSKETEARLTA	1.8777		
		ATGCSSHSKETEARL	1.9224		
		LATGCSSHSKETEAR	1.8273		
		DVESLRVERLAAPAA	0.7976		
		GGSVGGGLARLGAKI	1.0905		
		ARLGAKIGGKAAEMT	1.5589		
		RLGAKIGGKAAEMTA	1.5994		

at significant levels (Figures 3F and G). Among innate immune cells, the outcomes showed elevated macrophage activity (Figure 3H). Therefore, these results showed that our vaccine design could efficiently provide the basis of im-

munity against *P. aeruginosa* infections and trigger the immune response.

Figure 2. Schematic representation of the multi-epitope-designed vaccine construct. The following linkers connected epitopes: (1) EAAAK, (2) GGGGS, and (3) HEYGAEALERAG. The AAY and GPGPG linkers, shown in the figure, connected cytotoxic T lymphocyte and helper T lymphocyte epitopes, respectively (Abbreviations: Met, methionine; GM-CSF, granulocyte-macrophage colony-stimulating factor; CTL, cytotoxic T lymphocyte; HTL, helper T lymphocyte; His, histidine).

Figure 3. Immune simulation results by C-ImmSim. A, Antigen and immunoglobulins; B, B-cell population; C, B-cell population per state; D, T helper cell population per state; E, T cytotoxic cell population per state; F, T helper cell classes' switch; G, production of cytokine and interleukins; and H, macrophage population per state.

4.4. Secondary, Tertiary Recognition, and Verification of the Chimeric Vaccine Construct

A high percentage of random coils and helices in the second construct of the multi-epitope protein was predicted using GOR V demonstrated a 481-amino-acid-long construct, including 7.07% of strands, 59.39% of helices, and 40.54% of random coils, which consisted of the forma-

tion of stable antigenic epitopes (Figure 4A).

According to a de novo template modeling-helix bundle topology, from 10 cases of the proposed models with a template modeling-score below 0.4, the best model indicated an approximately correct topology of the template modeling-helix assembly was chosen. This structure's template modeling score and the root-mean-square deviation

Figure 4. A, graphical outcomes for secondary structure prediction of multi-epitope vaccine by the GOR V server. Then, the multi-epitope vaccine modeling and refinement were carried out; B, the initial tertiary structure was produced by the I-TASSER server presenting; D, the z-score of the initial model was -9.81; E, 88.030% of the residues in favored regions, 8.229% in allowed regions, and 3.741% in disallowed regions; C, the refined tertiary structure was achieved by the GalaxyRefine server presenting; F, the z-score of the refined model was -9.96; G, 94.26, 3.741, and 1.995% of the residues in favored, allowed, and disallowed regions, respectively.

(RMSD) were 0.477 and 6.65. The template modeling score determines the similarity between 2 structures by a score between 0 and 1, in which 1 presents a good match with 2 structures (Figures 4B and C). After determining the most suitable model, a refinement process was performed via the GalaxyWeb server to enhance structure quality. Consequently, the server produced 5 refined models (see Appendix 3). We analyzed initial and refined models to perceive their differences and select the best model. The structural validation and reliability of the predicted model of the chimeric vaccine were carried out by different online tools, such as ERRAT, Verify-3D, Ramachandran plot (Figure 4D-G), PROCHECK, and RAMPAGE (Table 2).

4.5. B-Cell Epitope Prediction

The selected PDB format of the chimeric vaccine was entered into the ElliPro server. We determined the minimum score as default (0.5) to select the epitope prediction parameter. Two epitopes were predicted with scores ranging from 0.658 to 0.742 (see Figure 5).

4.6. Investigation of Stability Between Vaccine Construct and TLR4

For further assessment of the binding affinity between homology modeling of the construct and TLR4, molecular docking accomplished by the ClusPro 2.0 server produced 30 clusters of protein-receptor complexes, accompanied

Table 2. The Evaluation of the 3D Structure^a

Models	Ramachandran Plot			Z-Score	ERRAT	Verify 3D (%)
	Favored	Allowed	Disallowed			
Initial	88.030	8.229	3.741	-9.81	72.45	81.876
Refined	94.26	3.741	1.995	-9.96	75.05	87.11

^a All the results confirmed that the refined model was better than the initial model.

No.	Residues	Number of residues	Score	3D structure
1	A:A349, A:R350, A:L351, A:G352, A:A353, A:K354, A:I355, A:G356, A:G357, A:K358, A:A359, A:A377, A:E378, A:H382, A:E387, A:E390, A:R391, A:A392, A:G393, A:V394, A:E395, A:L396, A:A397, A:L398, A:S399, A:Y400, A:G401, A:E402, A:Y403, A:H404, A:D405, A:V406, A:R407, A:G408, A:T409, A:K410, A:K411, A:V412, A:G413, A:Y414, A:G415, A:E416, A:S417, A:R418, A:P419, A:V420, A:A421, A:D422, A:N423, A:A424, A:T425, A:A426, A:E427, A:K428, A:K429, A:L430, A:D431, A:A432, A:I433, A:Y434, A:H435, A:F436, A:G437, A:T438, A:P439, A:G440, A:V441, A:G442, A:L443, A:R444, A:P445, A:K446, A:K447, A:T448, A:G449, A:C450, A:S451, A:S452, A:H453, A:S454, A:K455, A:E456, A:T457, A:E458, A:A459, A:R460, A:L461, A:T462, A:A463, A:H464, A:E465, A:Y466, A:G467, A:A468, A:E469, A:A470, A:L471, A:E472, A:R473, A:A474, A:G475, A:H476, A:H477, A:H478, A:H479, A:H480, A:H481	107	0.742
2	A:M1, A:E2, A:A3, A:A4, A:A5, A:K6, A:A7, A:P8, A:A9, A:R10, A:S11, A:P12, A:S13, A:P14, A:S15, A:T16, A:Q17, A:P18, A:W19, A:E20, A:H21, A:V22, A:N23, A:I25, A:Q26, A:R29, A:R30, A:L32, A:N33, A:L34, A:S35, A:R36, A:D37, A:T38, A:A39, A:A40, A:E41, A:M42, A:N43, A:E44, A:T45, A:V46, A:E47, A:V48, A:I49, A:S50, A:E51, A:M52, A:F53, A:D54, A:L55, A:Q56, A:E57, A:P58, A:T59, A:C60, A:T63, A:E66, A:L67, A:Q70, A:G71, A:L72, A:R73, A:G74, A:S75, A:L76, A:T77, A:K78, A:L79, A:K80, A:G81, A:C94, A:P95, A:P96, A:T97, A:P98, A:E99, A:T100, A:S101, A:T108, A:E110, A:K113, A:E114, A:N115, A:L116, A:K117, A:D118, A:C127, A:W128, A:E129, A:P130, A:V131, A:Q132, A:E133, A:G134, A:G135, A:G136, A:S137, A:L138, A:D140, A:E143, A:L144, A:L146, A:G147, A:P148, A:G149, A:P150, A:G151, A:V152, A:R153, A:D154, A:E159, A:Y160, A:G161, A:P162, A:G163, A:P164, A:G165, A:A166, A:Q167, A:A168, A:R169, A:A170, A:D171, A:E172, A:A173, A:E176, A:Y177, A:A179, A:E180, A:A181, A:L182, A:E183, A:R184, A:A185, A:G186, A:G187, A:G188, A:R189, A:G196, A:E197, A:S198, A:R199, A:P200, A:V201, A:A202, A:A203, A:Y204, A:V205, A:E206, A:G207, A:G208, A:R209, A:V210, A:N211, A:Y215, A:E217, A:S218, A:R219, A:A220, A:A221, A:Y222, A:E223, A:G224, A:G225, A:R226, A:V227, A:Y240, A:V244	169	0.658

Figure 5. Predicted conformational B-cell epitopes of the multi-epitope vaccine.

by respective free binding energy, as an output. The best-weighted score of the lowest energy and the center score were -1132.4 and -927.1. As our investigations, cluster 1 was adopted, which accurately occupied the receptor and created a stable ligand-receptor complex (Figure 6A).

The results of the MD simulation of the multi-epitope vaccine and TLR4 docked complex are demonstrated in Figure 6B. MD simulation of proteins provides an apparent measurement of their atoms and molecules' physical and stability movements. Therefore, the simulation was performed to illustrate the relative strength of the multi-epitope vaccine protein. The deformability and B-factor graphs of the vaccine/TLR4 complex represented the peaks describing the moderate level of deformability and precise correlation between normal mode analysis (NMA) and the PDB field of the docked complex (Figures 6C and D). The eigenvalue of the complex is represented in Figure 6E. The multi-epitope and TLR4 docked complex produced a

great eigenvalue of 1.094677e-05. Individual and cumulative variances are represented by red and green colored bars in the variance graph (Figure 6F). Figure 5G depicts the covariance map of the docked complex (red color, the correlated; white color, the uncorrelated; and blue color, the anti-correlated motions between residues). The elastic map of the docked complex, in which darker gray regions represent stiffer regions, points to the association between the atoms (Figure 6H).

4.7. Investigation of Codon Optimality, Bias, and Usage in the Translation of Chimeric Vaccine

Whenever the codon usage of the host varies from the organism, codon adaptation is utilized to achieve significant expression in the host. The JCat was applied to determine codon optimization for maximal protein expression in *E. coli* (K-12 strain). It was noted that the length of the produced complementary DNA (cDNA) sequence was

Figure 6. A, the interaction between toll-like receptor 4 (in light magenta color) and multi-epitope vaccine construct (yellow). The interaction was visualized with PyMol. Molecular dynamics between the chimeric vaccine and toll-like receptor 4 was administered utilizing the ClusPro server, and the product demonstrated the formation of a stable complex. In addition, the results of the molecular dynamics simulation study of multi-epitope vaccine and toll-like receptor 4 docked complex were illustrated. Here, B, normal mode analysis mobility; C, deformability; D, B-factor; E, eigenvalues; F, variance (red color illustrates individual variances, and green color shows cumulative variances); G, covariance map [correlated (red), uncorrelated (white), or anti-correlated (blue) motions]; and H, elastic network (darker gray regions demonstrate more stiffer regions).

1446 nucleotides. The CAI value was detected to be 1.0, revealing high gene expression (the optimum range is 0.8 - 1.0). Moreover, the average GC content (the optimal percentage is between 30 - 70%) of the improved sequence was 54.12% (Figure 7A). The predicted DNA sequence of the multi-epitope vaccine candidate (Figure 7C) was inserted into the pET-22b(+) vector plasmid between the HindIII and KsI restriction sites. The ultimately constructed vector is represented in Figure 7B.

5. Discussion

The current investigation was designed to build potential vaccines against *P. aeruginosa*, causing virulent and persistent infections despite antibiotic treatment. Recent studies have shown an increasing trend in the occurrence of multidrug-resistant (MDR) *P. aeruginosa* strains, which significantly limits the availability of chemotherapeutic agents for the treatment of patients and complicates the management of the disease (33, 34). With the emergence of MDR strains, *P. aeruginosa*-related infections are notoriously challenging to treat; hence, a possible vaccine was

predicted in this study to combat this pathogenic microorganism. The bacteria's 3 candidate proteins (OprF, OprI, and PopB) were recognized and chosen from the National Center for Biotechnology Information (NCBI) database to produce the vaccine construction. Since these antigenic proteins involve several crucial functions of *P. aeruginosa* and could provoke immune response effectively, these sequences were chosen for further analysis. Fito-Boncompagni et al. in 2011 proved that OprF had a prominent role in cellular adhesion and production of virulence-related factors, including biofilm (35). A study showed that immunization with OprF/OprI and flagellin B was effective against infection generated by mucoid and non-mucoid strains of *P. aeruginosa* in animal models (36). In a previous study, immunization with highly conserved PopB, a component of the type III secretion system, evoked Th17 responses and intensified *P. aeruginosa* from the spleen and lung after challenge in an animal model (37). Following our previous study, OprF/I and PopB could simultaneously make antibody-independent and antibody-dependent protection. Therefore, in this study, we determined to work on these antigenic epitopes to develop a more effective vac-

No.	Residues	Number of residues	Score	3D structure
1	A:A349, A:R350, A:L351, A:G352, A:A353, A:K354, A:I355, A:G356, A:G357, A:K358, A:A359, A:A377, A:E378, A:H382, A:E387, A:E390, A:R391, A:A392, A:G393, A:V394, A:E395, A:L396, A:A397, A:L398, A:S399, A:Y400, A:G401, A:E402, A:Y403, A:H404, A:D405, A:V406, A:R407, A:G408, A:T409, A:K410, A:K411, A:V412, A:G413, A:Y414, A:G415, A:E416, A:S417, A:R418, A:P419, A:V420, A:A421, A:D422, A:N423, A:A424, A:T425, A:A426, A:E427, A:K428, A:K429, A:L430, A:D431, A:A432, A:I433, A:Y434, A:H435, A:F436, A:G437, A:T438, A:P439, A:G440, A:V441, A:G442, A:L443, A:R444, A:P445, A:K446, A:K447, A:T448, A:G449, A:C450, A:S451, A:S452, A:H453, A:S454, A:K455, A:E456, A:T457, A:E458, A:A459, A:R460, A:L461, A:T462, A:A463, A:H464, A:E465, A:Y466, A:G467, A:A468, A:E469, A:A470, A:L471, A:E472, A:R473, A:A474, A:G475, A:H476, A:H477, A:H478, A:H479, A:H480, A:H481	107	0.742
2	A:M1, A:E2, A:A3, A:A4, A:A5, A:K6, A:A7, A:P8, A:A9, A:R10, A:S11, A:P12, A:S13, A:P14, A:S15, A:T16, A:Q17, A:P18, A:W19, A:E20, A:H21, A:V22, A:N23, A:I25, A:Q26, A:R29, A:R30, A:L32, A:N33, A:L34, A:S35, A:R36, A:D37, A:T38, A:A39, A:A40, A:E41, A:M42, A:N43, A:E44, A:T45, A:V46, A:E47, A:V48, A:I49, A:S50, A:E51, A:M52, A:F53, A:D54, A:L55, A:Q56, A:E57, A:P58, A:T59, A:C60, A:T63, A:E66, A:L67, A:Q70, A:G71, A:L72, A:R73, A:G74, A:S75, A:L76, A:T77, A:K78, A:L79, A:K80, A:G81, A:C94, A:P95, A:P96, A:T97, A:P98, A:E99, A:T100, A:S101, A:T108, A:E110, A:K113, A:E114, A:N115, A:L116, A:K117, A:D118, A:C127, A:W128, A:E129, A:P130, A:V131, A:Q132, A:E133, A:G134, A:G135, A:G136, A:S137, A:L138, A:D140, A:E143, A:L144, A:L146, A:G147, A:P148, A:G149, A:P150, A:G151, A:V152, A:R153, A:D154, A:E159, A:Y160, A:G161, A:P162, A:G163, A:P164, A:G165, A:A166, A:Q167, A:A168, A:R169, A:A170, A:D171, A:E172, A:A173, A:E176, A:Y177, A:A179, A:E180, A:A181, A:L182, A:E183, A:R184, A:A185, A:G186, A:G187, A:G188, A:R189, A:G196, A:E197, A:S198, A:R199, A:P200, A:V201, A:A202, A:A203, A:Y204, A:V205, A:E206, A:G207, A:G208, A:R209, A:V210, A:N211, A:Y215, A:E217, A:S218, A:R219, A:A220, A:A221, A:Y222, A:E223, A:G224, A:G225, A:R226, A:V227, A:Y240, A:V244	169	0.658

Figure 7. Codon adaptation and in silico cloning. A, The results of the codon adaptation investigation of the best multi-epitope vaccine; B, the cloning of the gene sequence of vaccine constructs into pET-22b (+) vector, presenting the region of choice in red color surrounded between HindIII (173) and KasI (812), while the vector was displayed in black lines; C, the construct of multi-epitope vaccine.

cine.

The most important factor in improving computational analysis is the structural study of the vaccine candidate, predictions of antigenicity, investigating epitopes regarding a vast diversity of HLAs, and assessment of interactions with human receptors (38). The principal feature for the vaccine approach is the determination of corrected CTLs, HTLs, and B-cells epitopes, which can produce neutralized antibodies against the pathogenic microorganism and provoke the Th cells and CTL response (39).

The connection between epitopes produced by applying linkers can reduce the probability of junctional antigens generation and improve antigen-presenting cells (40). The structural flexibility and rigidity of a suitable vaccine construct are relevant to choosing linkers. Regarding the study by Rahmani et al. (41), we designed a vaccine peptide with the following linkers: EAAAK, GGGS, GPGPG, HEYGAELERAG, AAY, and KK. EAAAK was applied between the adjuvant and Met to produce rigidity and decrease possible interference of other protein regions (42). GGGS was used between the adjuvant and CTL epitope to make better flexibility. The proteasomal and lysosomal systems (AAY and HEYGAELERAG) used GPGPG linkers as cleavage sites to provoke HTL immune response (43). Ultimately, B-cell epitopes were connected with the KK linker to maintain

their distinct immunogenic activity (44). This result illustrated that the selection and distribution linkers were suitable.

Various studies related to promising vaccine antigens for *P. aeruginosa* have indicated that Th1 and IFN- γ responses are linked to protection against this bacterial infection (45, 46). Concerning these observations, the choice of the GM-CSF adjuvant, as an additional component of the multi-epitope vaccine, seemed suitable. A study revealed that GM-CSF administration accompanied by a human immunodeficiency virus type 1 DNA vaccine increased the quality and quantity of vaccine immune T-cell responses. This event was carried out primarily via developing proliferating CD4+ T cells, which concurrently create IFN- γ , IL-2, and tumor necrosis factor- α (TNF- α) (47). Reali et al. noticed an improvement in the immune response following the local administration of GM-CSF in animal models (48). According to the result of the IFNepitope server analysis and IL4Pred, it was documented that IFN- γ -inducing epitopes and IL4-induced predicted could cause a long-lasting cellular response. The epitopes with high antigenic properties, low allergenicity, and non-toxicity were considered a vaccine candidate. Besides, the C-ImmSim server predicted a relevant antibody production immunoglobulin (G, M, G1, and G1+G2) after immunization, which is de-

fined as necessary for fighting against *Pseudomonas* infection. These outcomes indicate the probability of this vaccine candidate to provoke an effective immune response and defend against the infection.

The characteristic physicochemical analysis was performed for the chimeric protein. The aliphatic index of the vaccine constructs, which depends on the relative volume involved via the aliphatic amino acids, valine, and alanine, had the highest value among these proteins (69.79). According to Kyte and Doolittle, the negative GRAVY value exhibits a hydrophilic protein, and the positive one expresses hydrophobic characteristics (49); our proteins had the highest GRAVY value of -0.414. Moreover, the half-life was 30 hours in mammalian reticulocytes, > 20 hours in yeast, and > 10 hours in *E. coli*; it had the highest theoretical PI of 6.24. Due to an instability index of 31.92, the vaccine was considered stable. Thus, the physicochemical property analysis exhibited quite good results.

The secondary structure analysis illustrated that the vaccine construct determined random coils (40.54%), alpha helices (59.39%), and extended strand (7.07%). These data revealed that this structure was stable with a random coil structure, facilitating identification by immune system agents. Next, the tertiary structure prediction of the chimeric vaccine was accomplished by applying the I-TASSER server. The GalaxyRefine server refined and improved the structural disturbance for the primary model. Then, the predicted 3D model validation using verified software revealed that 94.26% of residues were located in the favored region. The mentioned results confirmed that the predicted structure model was stable, profoundly ordered, and contained high features.

TLRs are among the most investigated pattern recognition receptor (PRR) families (50), which can identify explicitly bacterial lipopolysaccharide (LPS). Their activation significantly contributes to the construction of pro-inflammatory cytokines, for instance, TNF, IL-6, and chemokines. The molecular docking was performed to recognize whether all the epitopes could connect with their respective MHC I and II alleles or not. The results manifested interactions between the multi-epitope-designed vaccine and receptor, using ClusPro 2.0, relying on the lowest energy score (-1132.4) carried out thoroughly. Then, the MD simulation investigation, administered by the online tool iMODS, showed that the TLR4/multi-epitope docked complex was stable, including a valid eigenvalue of 1.094677e-05.

Codon usage and in silico cloning practices were conducted with the predicted CAI value of 1.0. The result of the DNA sequence showed that it contained a high value of favorable codons and a considerate amount of GC con-

tent of 54.12% in *E. coli* strain K12. Ultimately, the pET-22b (+) vector, containing the ultimate vaccine, was inserted to construct a more efficient vaccine candidate in *E. coli* cells. Peluso et al used both recombinant His-conjugated OprF (acquired from cloning the oprF gene into the pET-28a expression vector) and native OprF (isolated and purified from PAO1). They urged that DCs induced with these antigens could provoke Th1 cells and cause resistance to infection caused by either a clinically isolated mucoid or the PAO1 strain (51). This result is consistent with the result obtained by Wu et al who indicated a high level of IL-4, IL-17, and IFN- γ in animal models with the PopB and curdlan adjuvant compared to the control group (37). Moreover, our result was consistent with Hu et al, showing that TLR4 was crucial in host resistance to *P. aeruginosa*, and its deficiency led to increased polymorphonuclear (PMN) infiltration and pro-inflammatory cytokine production and a susceptible phenotype (52).

Altogether, the present study provides a snapshot of a multi-epitope vaccine against *P. aeruginosa*. We conceive that this research can be used as a framework for future studies to improve different types of *P. aeruginosa* vaccine. However, more in vitro and in vivo studies are needed to confirm the findings of this study.

5.1. Conclusions

The *Pseudomonas*-host relationship complexity in each stage of infection is not apparent, preventing the development of an approved vaccine. In the current study, we investigated a multi-epitope chimeric vaccine using different computational studies based on protective antigens of *P. aeruginosa* (OprF, OprI, and PopB). A reasonably chimeric-designed vaccine is required to develop both innate and adaptive immunity according to the presence of several T-cell and B-cell epitopes, IL-4 and IFN- γ inducing epitopes, and indicated stability-binding affinity with the immune-receptor TLR4. Hence, to generate potential vaccines against *P. aeruginosa*, we suggest that specialists construct and purify this chimeric vaccine and investigate the vaccine efficacy before and after challenge into appropriate models.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes

Authors' Contribution: Study concept and design, M. G., and H. G.; Analysis and interpretation of data, F. S., and A. SCH.; Drafting of the manuscript, MH. YI.; Critical revision of the manuscript for important intellectual content, M. G., H. G., F. S., A. SCH., and MH. YI.; Statistical analysis, M. G.

Conflict of Interests: The authors declared no conflict of interest.

Ethical Approval: Ethical approval for this study was obtained from the Ethics Committee of Shahid Beheshti University of Medical Sciences in Tehran, Iran (IR.SBMU.MSP.REC.1398.999).

Funding/Support: This study was performed as part of the PhD thesis of Fattaneh Sabzehali and was funded by the Research Department of the School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Grant No. 14583).

Informed Consent: This manuscript is a bioinformatic study toward the development of a vaccine against *Pseudomonas aeruginosa*. We did not use the clinical samples. This study does not require informed consent, but the entire procedures were approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences in Tehran, Iran (IR.SBMU.MSP.REC.1398.999).

References

- Baker SM, McLachlan JB, Morici LA. Immunological considerations in the development of *Pseudomonas aeruginosa* vaccines. *Hum Vaccin Immunother*. 2020;**16**(2):412–8. doi: [10.1080/21645515.2019.1650999](#). [PubMed: [31368828](#)]. [PubMed Central: [PMC7062425](#)].
- Navidinia M. The clinical importance of emerging ESKAPE pathogens in nosocomial infections. *Arch Adv Biosci*. 2016;**7**(3):43–57.
- Blot S, Koulenti D, Dimopoulos G, Martin C, Komnos A, Krueger WA, et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients*. *Crit Care Med*. 2014;**42**(3):601–9. doi: [10.1097/01.ccm.0000435665.07446.50](#). [PubMed: [24158167](#)].
- Douglas MW, Mulholland K, Denyer V, Gottlieb T. Multi-drug resistant *Pseudomonas aeruginosa* outbreak in a burns unit—an infection control study. *Burns*. 2001;**27**(2):131–5. doi: [10.1016/S0305-4179\(00\)00084-X](#). [PubMed: [11226649](#)].
- Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev*. 2009;**22**(4):582–610. doi: [10.1128/CMR.00040-09](#). [PubMed: [19822890](#)]. [PubMed Central: [PMC2772362](#)].
- Navidinia M, Goudarzi M. Overview Perspective of Bacterial Strategies of Resistance to Biocides and Antibiotics. *Arch Clin Infect Dis*. 2019;**In Press**. doi: [10.5812/archcid.65744](#).
- Jafari M, Fallah F, Borhan RS, Navidinia M, Karimi A, Rafiei Tabatabaei S, et al. The First Report of CMY, aac (6')-Ib and 16S rRNA Methylase Genes Among *Pseudomonas aeruginosa* Isolates From Iran. *Arch Pediatr Infect Dis*. 2013;**2**(2):109–12. doi: [10.5812/pedinfect.11392](#).
- Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of *Pseudomonas aeruginosa* strains producing high levels of persister cells in patients with cystic fibrosis. *J Bacteriol*. 2010;**192**(23):6191–9. doi: [10.1128/JB.01651-09](#). [PubMed: [20935098](#)]. [PubMed Central: [PMC2981199](#)].
- Vincent JL. Vaccine development and passive immunization for *Pseudomonas aeruginosa* in critically ill patients: a clinical update. *Future Microbiol*. 2014;**9**(4):457–63. doi: [10.2217/fmb.14.10](#). [PubMed: [24810345](#)].
- Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid *Pseudomonas aeruginosa*. *Infect Immun*. 2009;**77**(6):2356–66. doi: [10.1128/IAI.00054-09](#). [PubMed: [19349426](#)]. [PubMed Central: [PMC2687341](#)].
- Singh S, Barr H, Liu YC, Robins A, Heeb S, Williams P, et al. Granulocyte-macrophage colony stimulatory factor enhances the pro-inflammatory response of interferon-gamma-treated macrophages to *Pseudomonas aeruginosa* infection. *PLoS One*. 2015;**10**(2). e0117447. doi: [10.1371/journal.pone.0117447](#). [PubMed: [25706389](#)]. [PubMed Central: [PMC4338139](#)].
- El-Manzalawy Y, Honavar V. Recent advances in B-cell epitope prediction methods. *Immunome Res*. 2010;**6 Suppl 2**. S2. doi: [10.1186/1745-7580-6-S2-S2](#). [PubMed: [21067544](#)]. [PubMed Central: [PMC2981878](#)].
- Costa JG, Faccendini PL, Sferco SJ, Lagier CM, Marcipar IS. Evaluation and comparison of the ability of online available prediction programs to predict true linear B-cell epitopes. *Protein Pept Lett*. 2013;**20**(6):724–30. doi: [10.2174/0929866511320060011](#). [PubMed: [22973845](#)].
- Doytchinova IA, Flower DR. Vaxijen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. *BMC Bioinformatics*. 2007;**8**:4. doi: [10.1186/1471-2105-8-4](#). [PubMed: [17207271](#)]. [PubMed Central: [PMC1780059](#)].
- Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. *Proteins*. 2006;**65**(1):40–8. doi: [10.1002/prot.21078](#). [PubMed: [16894596](#)].
- Saha S, Raghava GP. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. *Nucleic Acids Res*. 2006;**34**(Web Server issue):W202–9. doi: [10.1093/nar/gkl343](#). [PubMed: [16844994](#)]. [PubMed Central: [PMC1538830](#)].
- Hebdtich M, Carballo-Amador MA, Charonis S, Curtis R, Warwicker J. Protein-Sol: a web tool for predicting protein solubility from sequence. *Bioinformatics*. 2017;**33**(19):3098–100. doi: [10.1093/bioinformatics/btx345](#). [PubMed: [28575391](#)]. [PubMed Central: [PMC5870856](#)].
- Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein Identification and Analysis Tools on the ExPASy Server. In: Walker JM, editor. *The Proteomics Protocols Handbook*. New Jersey, USA: Humana Press; 2005. p. 571–607. doi: [10.1385/1-59259-890-0-571](#).
- Garnier J, Gibrat J, Robson B. [32] GOR method for predicting protein secondary structure from amino acid sequence. *Computer Methods for Macromolecular Sequence Analysis*. New York, USA: Academic Press; 1996. p. 540–53. doi: [10.1016/S0076-6879\(96\)66034-0](#).
- Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. *Nat Methods*. 2015;**12**(1):7–8. doi: [10.1038/nmeth.3213](#). [PubMed: [25549265](#)]. [PubMed Central: [PMC4428668](#)].
- Yuan S, Chan H, Hu Z. Using PyMOL as a platform for computational drug design. *Wiley Interdiscip Rev Comput Mol Sci*. 2017;**7**(2). doi: [10.1002/wcms.1298](#).
- Heo L, Park H, Seok C. GalaxyRefine: Protein structure refinement driven by side-chain repacking. *Nucleic Acids Res*. 2013;**41**(Web Server issue):W384–8. doi: [10.1093/nar/gkt458](#). [PubMed: [23737448](#)]. [PubMed Central: [PMC3692086](#)].
- Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res*. 2007;**35**(Web Server issue):W407–10.

- doi: [10.1093/nar/gkm290](https://doi.org/10.1093/nar/gkm290). [PubMed: [17517781](https://pubmed.ncbi.nlm.nih.gov/17517781/)]. [PubMed Central: [PMC1933241](https://pubmed.ncbi.nlm.nih.gov/PMC1933241/)].
24. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. *BMC Bioinformatics*. 2008;**9**:514. doi: [10.1186/1471-2105-9-514](https://doi.org/10.1186/1471-2105-9-514). [PubMed: [19055730](https://pubmed.ncbi.nlm.nih.gov/19055730/)]. [PubMed Central: [PMC2607291](https://pubmed.ncbi.nlm.nih.gov/PMC2607291/)].
25. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. *BMC Bioinformatics*. 2007;**8**:424. doi: [10.1186/1471-2105-8-424](https://doi.org/10.1186/1471-2105-8-424). [PubMed: [17973982](https://pubmed.ncbi.nlm.nih.gov/17973982/)]. [PubMed Central: [PMC2194739](https://pubmed.ncbi.nlm.nih.gov/PMC2194739/)].
26. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. *BMC Bioinformatics*. 2010;**11**:568. doi: [10.1186/1471-2105-11-568](https://doi.org/10.1186/1471-2105-11-568). [PubMed: [21092157](https://pubmed.ncbi.nlm.nih.gov/21092157/)]. [PubMed Central: [PMC2998531](https://pubmed.ncbi.nlm.nih.gov/PMC2998531/)].
27. Dhanda SK, Vir P, Raghava GP. Designing of interferon-gamma inducing MHC class-II binders. *Biol Direct*. 2013;**8**:30. doi: [10.1186/1745-6150-8-30](https://doi.org/10.1186/1745-6150-8-30). [PubMed: [24304645](https://pubmed.ncbi.nlm.nih.gov/24304645/)]. [PubMed Central: [PMC4235049](https://pubmed.ncbi.nlm.nih.gov/PMC4235049/)].
28. Castiglione F. *C-ImmSim: a model of immunological models*. Italy: National Research Council; 2017.
29. Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, et al. The ClusPro web server for protein-protein docking. *Nat Protoc*. 2017;**12**(2):255–78. doi: [10.1038/nprot.2016.169](https://doi.org/10.1038/nprot.2016.169). [PubMed: [28079879](https://pubmed.ncbi.nlm.nih.gov/28079879/)]. [PubMed Central: [PMC5540229](https://pubmed.ncbi.nlm.nih.gov/PMC5540229/)].
30. Lopez-Blanco JR, Garzon JI, Chacon P. iMod: multipurpose normal mode analysis in internal coordinates. *Bioinformatics*. 2011;**27**(20):2843–50. doi: [10.1093/bioinformatics/btr497](https://doi.org/10.1093/bioinformatics/btr497). [PubMed: [21873636](https://pubmed.ncbi.nlm.nih.gov/21873636/)].
31. Ali M, Pandey RK, Khatoon N, Narula A, Mishra A, Prajapati VK. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. *Sci Rep*. 2017;**7**(1):9232. doi: [10.1038/s41598-017-09199-w](https://doi.org/10.1038/s41598-017-09199-w). [PubMed: [28835708](https://pubmed.ncbi.nlm.nih.gov/28835708/)]. [PubMed Central: [PMC5569093](https://pubmed.ncbi.nlm.nih.gov/PMC5569093/)].
32. McGuffie MJ, Barrick JE. pLannotate: engineered plasmid annotation. *Nucleic Acids Res*. 2021;**49**(W1):W516–22. doi: [10.1093/nar/gkab374](https://doi.org/10.1093/nar/gkab374). [PubMed: [34019636](https://pubmed.ncbi.nlm.nih.gov/34019636/)]. [PubMed Central: [PMC8262757](https://pubmed.ncbi.nlm.nih.gov/PMC8262757/)].
33. Voruganti VS, Klein GL, Lu HX, Thomas S, Freeland-Graves JH, Herndon DN. Impaired zinc and copper status in children with burn injuries: need to reassess nutritional requirements. *Burns*. 2005;**31**(6):711–6. doi: [10.1016/j.burns.2005.04.026](https://doi.org/10.1016/j.burns.2005.04.026). [PubMed: [16006043](https://pubmed.ncbi.nlm.nih.gov/16006043/)].
34. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with *Pseudomonas aeruginosa*. *J Pediatr*. 1990;**116**(5):714–9. doi: [10.1016/S0022-3476\(05\)82653-8](https://doi.org/10.1016/S0022-3476(05)82653-8). [PubMed: [2109790](https://pubmed.ncbi.nlm.nih.gov/2109790/)].
35. Fito-Boncompagni L, Chapalain A, Bouffartigues E, Chaker H, Lesouhaitier O, Gicquel G, et al. Full virulence of *Pseudomonas aeruginosa* requires OprF. *Infect Immun*. 2011;**79**(3):1176–86. doi: [10.1128/IAI.00850-10](https://doi.org/10.1128/IAI.00850-10). [PubMed: [21189321](https://pubmed.ncbi.nlm.nih.gov/21189321/)]. [PubMed Central: [PMC3067511](https://pubmed.ncbi.nlm.nih.gov/PMC3067511/)].
36. Hassan R, El-Naggar W, Abd El-Aziz AM, Shaaban M, Kenawy HI, Ali YM. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid *Pseudomonas aeruginosa*. *J Microbiol Immunol Infect*. 2018;**51**(3):312–20. doi: [10.1016/j.jmii.2016.08.014](https://doi.org/10.1016/j.jmii.2016.08.014). [PubMed: [28291719](https://pubmed.ncbi.nlm.nih.gov/28291719/)].
37. Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, et al. Th17-stimulating protein vaccines confer protection against *Pseudomonas aeruginosa* pneumonia. *Am J Respir Crit Care Med*. 2012;**186**(5):420–7. doi: [10.1164/rccm.201202-0182OC](https://doi.org/10.1164/rccm.201202-0182OC). [PubMed: [22723292](https://pubmed.ncbi.nlm.nih.gov/22723292/)]. [PubMed Central: [PMC3443805](https://pubmed.ncbi.nlm.nih.gov/PMC3443805/)].
38. Negahdaripour M, Nezafat N, Eslami M, Ghoshoon MB, Shoolian E, Najafipour S, et al. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine. *Infect Genet Evol*. 2018;**58**:96–109. doi: [10.1016/j.meegid.2017.12.008](https://doi.org/10.1016/j.meegid.2017.12.008). [PubMed: [29253673](https://pubmed.ncbi.nlm.nih.gov/29253673/)].
39. Chaplin DD. Overview of the immune response. *J Allergy Clin Immunol*. 2010;**125**(2 Suppl 2):S3–23. doi: [10.1016/j.jaci.2009.12.980](https://doi.org/10.1016/j.jaci.2009.12.980). [PubMed: [20176265](https://pubmed.ncbi.nlm.nih.gov/20176265/)]. [PubMed Central: [PMC2923430](https://pubmed.ncbi.nlm.nih.gov/PMC2923430/)].
40. Ojha R, Nandani R, Prajapati VK. Contriving multi-epitope subunit vaccine by exploiting structural and nonstructural viral proteins to prevent Epstein-Barr virus-associated malignancy. *J Cell Physiol*. 2019;**234**(5):6437–48. doi: [10.1002/jcp.27380](https://doi.org/10.1002/jcp.27380). [PubMed: [30362500](https://pubmed.ncbi.nlm.nih.gov/30362500/)].
41. Rahmani A, Bae M, Rostamtabar M, Karkhah A, Alizadeh S, Tourani M, et al. Development of a conserved chimeric vaccine based on helper T-cell and CTL epitopes for induction of strong immune response against *Schistosoma mansoni* using immunoinformatics approaches. *Int J Biol Macromol*. 2019;**141**:125–36. doi: [10.1016/j.ijbiomac.2019.08.259](https://doi.org/10.1016/j.ijbiomac.2019.08.259). [PubMed: [31479669](https://pubmed.ncbi.nlm.nih.gov/31479669/)].
42. Lee SJ, Shin SJ, Lee MH, Lee MG, Kang TH, Park WS, et al. A potential protein adjuvant derived from *Mycobacterium tuberculosis* Rv0652 enhances dendritic cells-based tumor immunotherapy. *PLoS One*. 2014;**9**(8):e104351. doi: [10.1371/journal.pone.0104351](https://doi.org/10.1371/journal.pone.0104351). [PubMed: [25102137](https://pubmed.ncbi.nlm.nih.gov/25102137/)]. [PubMed Central: [PMC4125215](https://pubmed.ncbi.nlm.nih.gov/PMC4125215/)].
43. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, et al. A rational strategy to design multi-epitope immunogens based on multiple Th lymphocyte epitopes. *J Immunol*. 2002;**168**(11):5499–506. doi: [10.4049/jimmunol.168.11.5499](https://doi.org/10.4049/jimmunol.168.11.5499). [PubMed: [12023344](https://pubmed.ncbi.nlm.nih.gov/12023344/)].
44. Khan MT, Islam MJ, Parihar A, Islam R, Jerin TJ, Dhote R, et al. Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2. *Inform Med Unlocked*. 2021;**24**:100578. doi: [10.1016/j.imu.2021.100578](https://doi.org/10.1016/j.imu.2021.100578). [PubMed: [33898733](https://pubmed.ncbi.nlm.nih.gov/33898733/)]. [PubMed Central: [PMC8057924](https://pubmed.ncbi.nlm.nih.gov/PMC8057924/)].
45. Ding B, von Specht BU, Li Y. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to *Pseudomonas aeruginosa*. *Vaccine*. 2010;**28**(25):4119–22. doi: [10.1016/j.vaccine.2010.04.028](https://doi.org/10.1016/j.vaccine.2010.04.028). [PubMed: [20433804](https://pubmed.ncbi.nlm.nih.gov/20433804/)].
46. Mansouri E, Blome-Eberwein S, Gabelsberger J, Germann G, von Specht BU. Clinical study to assess the immunogenicity and safety of a recombinant *Pseudomonas aeruginosa* OprF-OprI vaccine in burn patients. *FEMS Immunol Med Microbiol*. 2003;**37**(2-3):161–6. doi: [10.1016/S0928-8244\(03\)00072-5](https://doi.org/10.1016/S0928-8244(03)00072-5). [PubMed: [12832120](https://pubmed.ncbi.nlm.nih.gov/12832120/)].
47. Santana VC, Almeida RR, Ribeiro SP, Ferreira LC, Kalil J, Rosa DS, et al. Co-administration of plasmid-encoded granulocyte-macrophage colony-stimulating factor increases human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4+ T-cell responses. *Mem Inst Oswaldo Cruz*. 2015;**110**(8):1010–6. doi: [10.1590/0074-02760150283](https://doi.org/10.1590/0074-02760150283). [PubMed: [26602876](https://pubmed.ncbi.nlm.nih.gov/26602876/)]. [PubMed Central: [PMC4708021](https://pubmed.ncbi.nlm.nih.gov/PMC4708021/)].
48. Reali E, Canter D, Zeytin H, Schlom J, Greiner JW. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. *Vaccine*. 2005;**23**(22):2909–21. doi: [10.1016/j.vaccine.2004.11.060](https://doi.org/10.1016/j.vaccine.2004.11.060). [PubMed: [15780740](https://pubmed.ncbi.nlm.nih.gov/15780740/)].
49. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. *J Mol Biol*. 1982;**157**(1):325–32. doi: [10.1016/0022-2836\(82\)90515-0](https://doi.org/10.1016/0022-2836(82)90515-0). [PubMed: [7108955](https://pubmed.ncbi.nlm.nih.gov/7108955/)].
50. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. *Clin Microbiol Rev*. 2003;**16**(4):637–46. doi: [10.1128/CMR.16.4.637-646.2003](https://doi.org/10.1128/CMR.16.4.637-646.2003). [PubMed: [14557290](https://pubmed.ncbi.nlm.nih.gov/14557290/)]. [PubMed Central: [PMC207104](https://pubmed.ncbi.nlm.nih.gov/PMC207104/)].
51. Peluso L, de Luca C, Bozza S, Leonardi A, Giovannini G, Lavorgna A, et al. Protection against *Pseudomonas aeruginosa* lung infection in mice by recombinant OprF-pulsed dendritic cell immunization. *BMC Microbiol*. 2010;**10**:9. doi: [10.1186/1471-2180-10-9](https://doi.org/10.1186/1471-2180-10-9). [PubMed: [20070893](https://pubmed.ncbi.nlm.nih.gov/20070893/)]. [PubMed Central: [PMC2820439](https://pubmed.ncbi.nlm.nih.gov/PMC2820439/)].
52. Hu XM, Zhang Q, Zhou RX, Wu YL, Li ZX, Zhang DY, et al. Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications. *World J Stem Cells*. 2021;**13**(5):386–415. doi: [10.4252/wjsc.v13.i5.386](https://doi.org/10.4252/wjsc.v13.i5.386). [PubMed: [34136072](https://pubmed.ncbi.nlm.nih.gov/34136072/)]. [PubMed Central: [PMC8176847](https://pubmed.ncbi.nlm.nih.gov/PMC8176847/)].